Dyslipidemia Management

Definition

Dyslipidemias are disorders of blood lipid levels encompassing elevated LDL-C (and total cholesterol), hypertriglyceridemia, and elevated Lp(a). Management targets atherogenic lipoprotein reduction to lower ASCVD risk and, for severe hypertriglyceridemia, prevention of acute pancreatitis. The 2026 ACC/AHA guideline represents the most current comprehensive framework, expanding focus beyond LDL-C to non-HDL-C, ApoB, and Lp(a) as therapeutic targets.

Epidemiology

• ASCVD (coronary heart disease, ischaemic stroke, PAD) is the leading cause of morbidity and mortality globally; elevated LDL-C and non-HDL-C are among the most prevalent and modifiable cardiovascular risk factors sources/lipid-aha-2026 (very high)
• Universal lipid screening from age 19 reflects the burden of dyslipidemia across the lifespan; prevalence is compounded by CKM syndrome (cardiometabolic-kidney disease), obesity, diabetes, and sedentary lifestyle sources/lipid-aha-2026 (very high)
• Familial hypercholesterolaemia (FH) affects approximately 1 in 250 individuals (heterozygous FH) — the most common monogenic disorder of atherogenic lipoprotein metabolism; lifetime ASCVD risk is substantially elevated, justifying cascade screening from age ≥2 y in affected families sources/lipid-aha-2026 (very high)
• Despite extensive CVOT evidence for statins, real-world LDL-C goal attainment in secondary prevention remains poor; this gap is addressed by the sequential nonstatin addition framework and was directly confronted by Ez-PAVE (2026), the first RCT to validate the <55 mg/dL vs <70 mg/dL target distinction sources/intensive-ldl-ezpave-nejm-2026 (high) sources/lipid-aha-2026 (very high)
• People with HIV on stable ART face excess cardiovascular risk independent of traditional risk factors; REPRIEVE demonstrated 35% MACE reduction with pitavastatin 4 mg, supporting statin therapy as primary prevention irrespective of calculated risk sources/lipid-esc-2025 (very high)

Pathophysiology

LDL-C, Non-HDL-C, and ApoB as Atherogenic Drivers

• LDL-C reflects cholesterol mass within LDL particles; non-HDL-C (= TC − HDL-C) captures cholesterol across all atherogenic particles (LDL, VLDL remnants/IDL, Lp(a)); non-HDL-C is a better ASCVD predictor than LDL-C alone and is routinely reportable from any lipid panel sources/lipid-aha-2026 (very high)
• ApoB provides the most direct measure of atherogenic particle number: every LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB molecule; a given LDL-C value can conceal elevated ApoB (small, dense LDL — more particles per unit cholesterol) or low ApoB (large, cholesterol-rich but fewer particles); discordance is most common in CKM syndrome, elevated TG ≥150 mg/dL, and diabetes sources/lipid-aha-2026 (very high)
• Mendelian randomisation studies and data from naturally occurring PCSK9 loss-of-function variants confirm that LDL-C lowering is causally and monotonically associated with CHD risk reduction; PCSK9 LOF variants confer up to 88% lifetime CHD risk reduction, forming the genetic rationale for PCSK9-targeted therapies sources/verve102-pcsk9-nejm-2026 (high)

PCSK9 Biology

• PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease synthesised primarily in hepatocytes; after secretion into plasma it binds hepatocyte surface LDL receptors (LDLR) and prevents LDLR recycling, directing the LDLR–PCSK9–LDL complex to lysosomal degradation → fewer surface LDLRs → less LDL-C cleared from plasma sources/inclisiran-orion-nejm-2020 (high)
• Inhibiting PCSK9 at any level — protein (mAb), mRNA (siRNA), or DNA (base editing) — increases LDLR recycling and reduces circulating LDL-C, consistently reducing MACE by ~15% per ~60% LDL-C reduction in large CVOTs sources/pcsk9-inhibitors-nrc-2018 (very high)

Hypertriglyceridaemia and Remnant Particle Atherogenicity

• Triglyceride-rich lipoproteins (VLDL, chylomicrons) are hydrolysed by lipoprotein lipase (LPL) to produce cholesterol-enriched remnant particles; remnants penetrate the arterial intima and promote atherogenesis through mechanisms analogous to LDL — this is the mechanistic basis for non-HDL-C and remnant cholesterol as ASCVD risk markers sources/olezarsen-essence-timi73b-nejm-2025 (high)
• ApoC-III inhibits LPL-mediated TG hydrolysis and impairs hepatic remnant uptake; loss-of-function APOC3 variants are associated with lower TG and reduced CHD risk; APOC3 inhibition (olezarsen, volanesorsen) exploits this pathway to substantially reduce TRL remnant burden sources/olezarsen-essence-timi73b-nejm-2025 (high)
• TG ≥1000 mg/dL (or ≥500 mg/dL in familial chylomicronemia syndrome) saturates LPL, causing chylomicronemia and directly risking acute pancreatitis — a mechanism and management framework distinct from the atherogenic pathway sources/lipid-aha-2026 (very high)

Diagnosis & Screening

Lipid Panel and Risk Screening

• Adults: lipid profile from age 19, every ≥5 years; more frequently with additional ASCVD risk factors sources/lipid-aha-2026 (very high)
• Children: universal screen ages 9–11; cascade screening from age ≥2 if family history of premature ASCVD or FH
• Martin/Hopkins or Sampson/NIH equations are preferred over Friedewald for LDL-C estimation (COR 1) — superior accuracy at low LDL-C and elevated TG levels
• Non-HDL-C (= TC – HDL-C) should be routinely reported; better predictor of ASCVD than LDL-C, correlates strongly with ApoB sources/lipid-aha-2026 (very high)
• Advanced lipoprotein testing (NMR, gel electrophoresis): NOT recommended for routine use (COR 3) sources/lipid-aha-2026 (very high)

ApoB — When and Why to Measure

• ApoB directly counts atherogenic particle number (1 ApoB per LDL, VLDL, Lp(a) particle) vs LDL-C which reflects cholesterol mass only sources/lipid-aha-2026 (very high)
• Discordance between LDL-C at goal but ApoB elevated = persistent atherogenic risk; most common in CKM syndrome, elevated TG ≥150 mg/dL, diabetes
• COR 2a: measure ApoB in adults on LLT (especially ASCVD, CKM, diabetes, elevated TG) once LDL-C/non-HDL-C goals met
• ApoB unaffected by fasting status; standardized assay
• ApoB <80 mg/dL corresponds to LDL-C <70 mg/dL target; ApoB <65 mg/dL corresponds to LDL-C <55 mg/dL

Treatment Goals by Risk Category

RCT evidence for the <55 vs <70 mg/dL target — Ez-PAVE (Lee YJ et al., NEJM 2026): n=3,048; established ASCVD (prior ACS 55.6%, stable angina 48.4%, revascularisation 67.2%, stroke/TIA 3.8%, PAD 8.7%); 17 South Korean sites; median follow-up 3.0 years; open-label. LDL-C achieved: 56 mg/dL (intensive) vs 66 mg/dL (conventional). Primary composite (CV death/nonfatal MI/nonfatal stroke/any revascularisation/UA hosp): HR 0.67 (95% CI 0.52–0.86; P=0.002) — 33% relative risk reduction; 6.6% vs 9.7% at 3 years. Components: nonfatal MI HR 0.46 (95% CI 0.23–0.91); any revascularisation HR 0.63 (95% CI 0.47–0.84) — primary driver; CV death NS (31 vs 29 all-cause deaths); nonfatal stroke NS; UA hosp NS. Safety: no difference in new-onset diabetes, muscle symptoms, aminotransferase or CK elevation, cancer, or cataracts; creatinine elevation (>1.5× baseline) lower in intensive group (1.2% vs 2.7%; P=0.004). Key caveats: only 60.8% reached <55 mg/dL target at 3 years (restricted PCSK9i access); East Asian population only; benefit driven by revascularisation (soft endpoint); fewer events than anticipated; 3-year follow-up. First RCT to validate the guideline shift to <55 mg/dL vs <70 mg/dL directly. (sources/intensive-ldl-ezpave-nejm-2026, rating: high)

Very High Risk ASCVD Definition (2023 CCD Guideline, Table 10): Multiple major ASCVD events OR 1 major event + ≥2 high-risk conditions. Major events: recent ACS (≤12 mo), prior MI, ischaemic stroke, symptomatic PAD (ABI <0.85 or prior revascularisation/amputation). High-risk conditions: age ≥65, FH, prior CABG/PCI outside the major event, DM, HTN, CKD (eGFR 15–59), current smoking, LDL ≥100 on max statin+ezetimibe, history of CHF. (sources/CCS-AHA-2023, rating: very high)

Management

Lifestyle

• Dietary pattern: emphasise fruits, vegetables, nuts, legumes, whole grains, fibre; replace saturated/trans fats with mono- and polyunsaturated fats (Mediterranean, DASH, vegan/vegetarian diets); clinical trial evidence shows replacing saturated fat (animal fats, tropical oils) with polyunsaturated fat reduces LDL-C concentrations — a causal CVD risk factor — and is associated with reduced CHD risk sources/diet-aha-2026 (very high)
• Fish oil supplements do NOT reduce CVD risk in otherwise healthy adults and may increase AF risk — important distinction from dietary fish (non-fried seafood), which is associated with lower CVD events and MI risk sources/diet-aha-2026 (very high). Note: icosapent ethyl (prescription-grade concentrated EPA, 4 g/day) carries a separate hypertriglyceridemia indication (COR 2b) but also carries AF risk
• Exercise: ≥150 min/wk moderate-to-vigorous aerobic + upper/lower body resistance exercise 2 d/wk
• Weight loss ≥5% associated with TG reduction ~4 mg/dL per kg lost; modest LDL-C reduction
• Healthy lifestyle halves ASCVD risk even in genetic predisposition (AHA Life's Essential 8)
• Dietary supplements (fish oil, red yeast rice, berberine, garlic, cinnamon, turmeric, plant sterols): no significant LDL-C reduction vs placebo (SPORT trial); COR 3: No Benefit — common patient perception of safety over FDA-approved medications is misleading sources/lipid-aha-2026 (very high). ESC 2025 explicitly recommends AGAINST dietary supplements or vitamins without documented safety and significant LDL-C-lowering efficacy (COR III B) sources/lipid-esc-2025 (very high)

Statin Therapy

• High-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg): ≥50% LDL-C reduction
• Moderate-intensity statins: 30–49% LDL-C reduction
• Statins are first-line for all major risk categories; CVOT evidence across primary and secondary prevention is extensive sources/lipid-aha-2026 (very high)
• High-intensity statin COR 1/A in secondary prevention: ≥50% LDL-C reduction target; generic formulations are cost-saving (high value); monitor lipids 4–12 weeks after initiation/dose change, then every 3–12 months sources/CCS-AHA-2023 (very high)
• Statin-associated diabetes risk: small but real in those with predisposing factors (BMI ≥30, fasting glucose ≥100, metabolic syndrome, HbA1c 6–6.4%); does NOT justify statin discontinuation — ASCVD benefit vastly outweighs sources/lipid-aha-2026 (very high)

Statin-Attributed Muscle Symptoms (SAMS)

• Bilateral symmetrical proximal myalgia/weakness within weeks of statin start; resolves within weeks of stopping
• Evaluate secondary causes before attributing to statin; CK measurement only for severe symptoms
• "Drucebo effect" (expectation-driven symptoms) is common
• Management escalation: reduce dose → alternate-day dosing → switch statin → add bempedoic acid/ezetimibe → PCSK9 mAb
• CoQ10 supplementation: NOT recommended (COR 3: No Benefit) sources/lipid-aha-2026 (very high)

Nonstatin LDL-C Lowering Agents

Bempedoic acid (ESC 2025): COR I B for statin-intolerant patients; COR IIa C as add-on to maximum tolerated statin + ezetimibe. CLEAR Outcomes: 13% MACE reduction (HR 0.87) in statin-intolerant patients. Adverse effects: hyperuricaemia/gout risk, raised liver enzymes, renal impairment sources/lipid-esc-2025 (very high)

Ezetimibe for very high risk + LDL ≥70 mg/dL on max statin — COR 2a/B-R: IMPROVE-IT 7% relative RRR; highest benefit in TRS2P ≥3 high-risk features (19% RRR, 6.3% ARR); generic ezetimibe is high value (<$50K/QALY). Add ezetimibe before PCSK9 mAb. (sources/CCS-AHA-2023, rating: very high)

PCSK9 mAb for very high risk + LDL ≥70 or non-HDL ≥100 on max statin + ezetimibe — COR 2a/A: FOURIER and ODYSSEY OUTCOMES: 15% MACE reduction each; uncertain economic value at current US prices (~$5,850/year; ICER ~$150K/QALY in most analyses). Bypass ezetimibe step only if ≥25% LDL reduction needed urgently. (sources/CCS-AHA-2023, rating: very high)

Bempedoic acid / inclisiran — COR 2b (CCS/AHA 2023): When ezetimibe and PCSK9 mAb are insufficient or not tolerated; LDL reduction 15–25% (bempedoic acid) and ~50% (inclisiran). Note: CLEAR Outcomes (bempedoic acid MACE benefit 13%) published after this guideline — may be upgraded in future revision. (sources/CCS-AHA-2023, rating: very high)

PCSK9 Inhibitor Evidence — FOURIER and ODYSSEY Outcomes

FOURIER Trial (Evolocumab; Sabatine 2017/2018 NEJM — reviewed in sources/pcsk9-inhibitors-nrc-2018):
n=27,564; established ASCVD (prior MI/stroke/symptomatic PAD); baseline LDL-C 92 mg/dL on optimised statin; evolocumab → median LDL-C 30 mg/dL (−59%); median follow-up 2.2 years. Primary endpoint (CV death/MI/stroke/revascularisation/UA hosp): HR 0.85 (95% CI 0.79–0.92). Key secondary (CV death/MI/stroke): HR 0.80. Fatal/nonfatal MI −21%; urgent revascularisation −27%. Benefit consistent even in patients with baseline LDL-C <70 mg/dL (achieved 21 mg/dL → 30% RRR). PAD subgroup: 42% reduction in major adverse limb events (HR 0.58). Time-dependent benefit: year 1 RRR 16% → post-year 1 RRR 25%. No excess DM, myalgias, neurocognitive events, or cataracts (EBBINGHAUS neurocognitive substudy, n=1,974: no between-group cognitive differences). (sources/pcsk9-inhibitors-nrc-2018 — very high)

ODYSSEY Outcomes Trial (Alirocumab; Schwartz 2018 ACC):
n=18,924; 1–12 months post-ACS; on high-intensity statin; alirocumab titrated to LDL-C 25–50 mg/dL; baseline LDL-C 87 mg/dL; median follow-up 2.8 years. Primary endpoint (CHD death/MI/ischaemic stroke/UA hosp): HR 0.85 (95% CI 0.78–0.93; P=0.003). Nominal all-cause mortality HR 0.85 (15% reduction; not statistically significant in testing hierarchy). Safety comparable to FOURIER. (sources/pcsk9-inhibitors-nrc-2018 — very high)

Key synthesis: Both PCSK9 mAbs reduce MACE by 15% on top of optimised statin therapy. Absolute LDL-C lowering is the primary driver of clinical benefit; relative risk reduction per mmol/L is consistent down to LDL-C <10 mg/dL with no safety signal (monotonic dose-response). Trials were short (2–3 years vs 5-year statin trials), likely underestimating true long-term benefit. Extrapolated to 5 years, absolute MACE reductions (~3%) are comparable to landmark statin trials. Neither trial showed CV mortality reduction — attributed to follow-up duration; ODYSSEY showed a nominal 15% all-cause mortality trend. See concepts/PCSK9-Inhibitors for full mechanism, genotype-specific FH dosing, and future directions.

Inclisiran — GalNAc-siRNA Phase 3 Evidence (ORION-10 and ORION-11)

Mechanism: Inclisiran is a chemically synthesised GalNAc-conjugated double-stranded siRNA. GalNAc enables hepatocyte-selective uptake via ASGPR; inside the hepatocyte, inclisiran loads into the RNA-induced silencing complex (RISC), catalytically cleaving PCSK9 mRNA → reduced PCSK9 synthesis → more LDL receptors recycled → lower LDL-C. Key pharmacokinetic feature: peak plasma level ~4 hours post-injection; cleared from plasma within 24–48 hours; intrahepatic RISC binding provides months of pharmacodynamic effect after plasma clearance. Reversal rate: ~2%/month if injections discontinued (effect may persist up to ~2 years). (sources/inclisiran-orion-nejm-2020 — high)

ORION-10 (Ray et al. NEJM 2020; US; established ASCVD; n=1,561; 540 days):

• SC 284 mg inclisiran on day 1, day 90, day 270, day 450; vs matching placebo
• Co-primary endpoint: LDL-C −52.3% at day 510 (95% CI −55.7 to −48.8; P<0.001)
• Time-adjusted LDL-C change day 90–540: −53.8% (P<0.001)
• Absolute LDL-C: −54.1 mg/dL at day 510
• PCSK9 reduction: −83.3% (95% CI −89.3 to −77.3)

ORION-11 (Ray et al. NEJM 2020; Europe/South Africa; ASCVD or risk equivalent [T2DM/HeFH/high-risk Framingham]; n=1,617; 540 days):

• Same dosing schedule as ORION-10
• Co-primary endpoint: LDL-C −49.9% at day 510 (95% CI −53.1 to −46.6; P<0.001)
• Time-adjusted LDL-C change day 90–540: −49.2% (P<0.001)
• Absolute LDL-C: −51.9 mg/dL at day 510
• PCSK9 reduction: −79.3% (95% CI −82.0 to −76.6)

Additional lipid effects (both trials): Reduced ApoB, non-HDL-C, total cholesterol, triglycerides, and Lp(a); increased HDL-C. Consistent across all subgroups (age, sex, BMI, race, renal function, statin intensity, diabetes).

Safety: Overall AE rate comparable to placebo; injection-site reactions mild and not persistent (2.6–4.7% excess vs placebo); no liver toxicity, no platelet changes, no excess cancer or deaths (2,166 person-years of exposure; 6,075 injections). Antidrug antibodies: low-titer, transient, non-neutralising. (sources/inclisiran-orion-nejm-2020 — high)

ORION-4 CVOT (Lancet 2024; n=15,000; HPS-4/TIMI 65): Primary composite (coronary death/MI/urgent coronary revascularisation): HR 0.84 (P=0.01) — did NOT meet the pre-specified significance threshold of P<0.005; statistically neutral by its own criteria. Directionally favourable but weaker CV outcomes evidence than evolocumab (FOURIER P<0.001) and alirocumab (ODYSSEY P=0.003).

Clinical positioning: Twice-yearly HCP-administered SC injection vs daily oral therapy or biweekly/monthly self-injection PCSK9 mAbs — designed to address poor long-term medication adherence. Included in ACC/AHA 2026 and CCS/AHA 2023 as a COR 2b option when ezetimibe and PCSK9 mAbs are insufficient or not tolerated. (sources/inclisiran-orion-nejm-2020 — high; see entities/Inclisiran)

Hypertriglyceridemia Management

• Lifestyle first: low added sugar, reduced refined carbs, saturated fat, alcohol; weight loss 5–10%; ≥150 min/wk moderate aerobic exercise sources/lipid-aha-2026 (very high)
• TG 150–499 mg/dL: statins reduce TG 10–30%; prioritise ASCVD risk reduction
• TG 500–999 mg/dL: add fibrates (fenofibrate preferred over gemfibrozil — fewer DDI) or prescription omega-3 fatty acids to reduce pancreatitis risk
• TG ≥1000 mg/dL: very-low-fat diet (<10–15% calories from fat); eliminate alcohol and added sugar; fibrates or omega-3 fatty acids; refer to RDN (COR 1)
• FCS (familial chylomicronemia syndrome): olezarsen (apoC3 ASO, 80 mg monthly SC) — COR 1 (ACC/AHA 2026); reduced pancreatitis episodes in BALANCE trial. Volanesorsen (anti-ApoC-III ASO, 300 mg/week SC; EMA-approved, ESC 2025 COR IIa B): 77% TG reduction in FCS (mean baseline TG 2209 mg/dL); reduces pancreatitis risk; adverse effects: thrombocytopenia (requires monitoring), injection-site reactions 60% sources/lipid-esc-2025 (very high). Region-specific formulary access (olezarsen = FDA; volanesorsen = EMA) will determine use.
• Icosapent ethyl (IPE): COR 2b (ACC/AHA 2026) / COR IIa B (ESC 2025) for adults ≥50 with ASCVD or diabetes + ≥1 risk factor + TG 150–499 mg/dL + LDL-C <100 mg/dL on statin (REDUCE-IT: 25% composite MACE reduction, but mineral oil placebo controversy); associated with increased AF and bleeding risk sources/lipid-aha-2026 sources/lipid-esc-2025 (both very high)
• Fibrates and niacin: NO proven ASCVD event reduction when added to statin therapy
• Gemfibrozil: NEVER combine with statins (serious myopathy risk)

APOC3 Inhibition — Olezarsen in Moderate HTG (ESSENCE-TIMI 73b, Phase 3, NEJM 2025):
Phase 3 RCT (n=1,349; TG 150–499 mg/dL + elevated CV risk; 96.3% already on LLT; monthly SC; 12 months): placebo-adjusted TG reduction −58.4 pp (50 mg) and −60.6 pp (80 mg) at 6 months (P<0.001 both). TG normalization (<150 mg/dL) achieved in 85–89% vs 12.5% placebo at 6 months. Beyond TG: remnant cholesterol reduced up to ~70%; VLDL-C ~57%; non-HDL-C ~22%; ApoB ~15%; LDL-C unchanged (mechanistically expected). Effects sustained at 12 months (−50.7 pp). No clinically significant hepatotoxicity or thrombocytopenia; mild injection-site reactions more common. Critical gap: no CV outcomes data — trial not powered for MACE; dedicated cardiovascular outcomes trial required to establish clinical benefit beyond lipid modification. (sources/olezarsen-essence-timi73b-nejm-2025, rating: high; see also concepts/APOC3-Inhibition, concepts/Hypertriglyceridemia-Management)

Monitoring

• Lipid profile 4–12 weeks after initiation or dose adjustment; every 6–12 months thereafter (COR 1)
• Routine CK measurement: NOT recommended (COR 3) unless severe symptoms
• Routine hepatic transaminase monitoring: NOT recommended (COR 3); check only if symptoms of hepatotoxicity

Special Populations

• CKD Stage 3+: Treat as ASCVD equivalent; no benefit of initiating statin in dialysis patients (2 negative RCTs)
• HIV (40–75 y, stable ART): Pitavastatin COR 1 (REPRIEVE trial); pitavastatin preferred — minimal CYP3A4 DDI with antiretrovirals sources/lipid-aha-2026 (very high). ESC 2025 extends this: statin recommended for ALL PWH aged ≥40 y in primary prevention, irrespective of estimated CV risk and LDL-C levels (COR I B) sources/lipid-esc-2025 (very high)
• Cancer/cardio-oncology (ESC 2025, COR IIa B): statins should be considered in patients at high/very high risk of chemotherapy-related CV toxicity to reduce anthracycline-induced cardiac dysfunction (STOP-CA: atorvastatin 40 mg → 22% vs 9% LVEF decline; P=.002) sources/lipid-esc-2025 (very high)
• Cancer survivors (life expectancy ≥2 y): Treat per standard guidelines; continue statins in active cancer unless DDI or life expectancy <1 y
• Pregnant women with TG ≥500 mg/dL: Fibrates (after first trimester) or prescription omega-3 fatty acids (COR 2a). Note: FDA removed statin use in pregnancy as a contraindication in 2024 (ACC/AHA 2026); statins should be avoided while lactating
• Age >75: LLT can be considered; individualized decision balancing ASCVD risk vs competing comorbidities

Secondary Prevention — Chronic Coronary Disease

• High-intensity statin COR 1/A: ≥50% LDL-C reduction target; generic formulations are cost-saving (high value); monitor lipids 4–12 weeks after initiation/dose change, then every 3–12 months. (sources/CCS-AHA-2023, rating: very high)
• Ez-PAVE — first RCT confirming <55 vs <70 mg/dL target superiority in ASCVD: n=3,048; South Korea; median 3.0 years; primary composite HR 0.67 (P=0.002); driven by revascularisation (HR 0.63) and nonfatal MI (HR 0.46); CV death/stroke NS; achieved LDL 56 vs 66 mg/dL; safety equivalent except lower creatinine elevation in intensive group. Supports guideline-recommended <55 mg/dL target for secondary prevention with direct target-level RCT evidence for the first time. (sources/intensive-ldl-ezpave-nejm-2026, rating: high)
• Ezetimibe for very high risk + LDL ≥70 mg/dL on max statin — COR 2a/B-R: IMPROVE-IT 7% relative RRR; highest benefit in TRS2P ≥3 high-risk features (19% RRR, 6.3% ARR); generic ezetimibe is high value (<$50K/QALY). Add ezetimibe before PCSK9 mAb. (sources/CCS-AHA-2023, rating: very high)
• PCSK9 mAb for very high risk + LDL ≥70 or non-HDL ≥100 on max statin + ezetimibe — COR 2a/A: FOURIER (evolocumab) and ODYSSEY OUTCOMES (alirocumab): 15% MACE reduction each; uncertain economic value at current US prices (~$5,850/year; ICER ~$150K/QALY in most analyses). Bypass ezetimibe step only if ≥25% LDL reduction needed urgently. (sources/CCS-AHA-2023, rating: very high)
• Icosapent ethyl 4 g/day — COR 2b/B-R: CCD patients with LDL <100 + TG 150–499 mg/dL on statin — REDUCE-IT: 25% MACE RRR, 20% CV death reduction (mineral oil placebo controversy same as ACC/AHA 2026 position); incident AF higher; dietary omega-3 NOT a substitute. (sources/CCS-AHA-2023, rating: very high)
• Bempedoic acid / inclisiran — COR 2b: When ezetimibe and PCSK9 mAb are insufficient or not tolerated; LDL reduction 15–25% (bempedoic acid) and ~50% (inclisiran). (sources/CCS-AHA-2023, rating: very high)
• Niacin, fenofibrate, dietary omega-3 supplements — COR 3 No Benefit: No CV event reduction on background statin (AIM-HIGH, HPS2-THRIVE, ACCORD-LIPID, PROMINENT, Cochrane omega-3 meta-analysis). Fenofibrate only for TG ≥500 to prevent pancreatitis. (sources/CCS-AHA-2023, rating: very high)

Secondary Prevention — ACS

• ACS patients have substantially higher ASCVD event rates than stable CCD (1-year rates of CV death/MI/stroke estimated 10–15% after ACS hospitalization) — justifying more aggressive LDL-C lowering. (sources/ACS-AHA-2025, rating: very high)
• High-intensity statin immediately post-ACS: Class I/A; benefit appears early and is independent of baseline LDL-C; do NOT de-escalate if tolerated. (sources/ACS-AHA-2025, rating: very high)
• Add nonstatin if LDL-C ≥70 mg/dL on maximal statin: Class I/A. Options: ezetimibe (IMPROVE-IT: 6.4% relative MACE reduction vs statin alone, median 6 years), alirocumab (ODYSSEY OUTCOMES: 15% MACE reduction), evolocumab (FOURIER). (sources/ACS-AHA-2025, rating: very high)
• Add nonstatin if LDL-C 55–69 mg/dL on maximal statin: Class IIa/B-R. PCSK9 inhibitor secondary analyses from FOURIER/ODYSSEY support monotonic benefit with lower achieved LDL-C even well below 50 mg/dL. No neurocognitive or muscle safety concern at very low LDL-C. (sources/ACS-AHA-2025, rating: very high)
• Concurrent ezetimibe initiation with maximal statin: Class IIb/B-R — reasonable if LDL-C goal not achieved on statin alone. (sources/ACS-AHA-2025, rating: very high). ESC 2025 upgrades this: high-intensity statin + ezetimibe should be considered together at index ACS hospitalization in treatment-naïve patients not expected to reach LDL-C goal with statin alone — "strike early and strong" strategy (COR IIa B) sources/lipid-esc-2025 (very high)
• Lipid reassessment: Fasting lipid panel 4–8 weeks after initiating/adjusting LLT post-ACS — Class I/C-LD. LDL-C decreases modestly beginning 24 hours after symptom onset; obtain lipid profile ASAP at presentation. (sources/ACS-AHA-2025, rating: very high)
• See entities/Acute-Coronary-Syndrome for full ACS secondary prevention context. (sources/ACS-AHA-2025, rating: very high)

Emerging Therapies

PCSK9 Base Editing (VERVE-102)

Base editing represents a fundamentally different approach to PCSK9 inhibition: rather than blocking circulating PCSK9 protein (mAbs) or reducing ongoing PCSK9 mRNA synthesis (siRNA), adenine base editing permanently alters hepatocyte DNA to inactivate PCSK9 gene expression — mimicking the effect of naturally occurring cardioprotective loss-of-function PCSK9 variants (which confer up to 88% lifetime CHD risk reduction).

VERVE-102 Mechanism: GalNAc-lipid nanoparticle (LNP) delivers mRNA encoding ABE8.8 adenine base editor + guide RNA targeting the PCSK9 5' intron 1 splice site. After ASGPR-mediated hepatocyte uptake, the base editor complex translocates to the nucleus and performs a single A→G substitution at the splice site, causing read-through to a stop codon and permanent loss of PCSK9 protein expression. No DNA double-strand breaks. LNP terminal half-life <20 hours (rapid plasma clearance); editing is permanent. (sources/verve102-pcsk9-nejm-2026 — high)

Heart-2 Phase 1 (Vafai/Kathiresan et al. NEJM 2026; n=35; HeFH or premature CAD on max statin ± ezetimibe; data cutoff Feb 2026):

• The 1.0 mg/kg LDL-C reduction (−62%) is comparable to ongoing PCSK9 inhibitor therapy (−40–60%) from a single infusion
• Reductions stable to ≥18 months (15 participants with ≥1 year follow-up); hepatocyte lifespan 200–300 days — edit persists through cell turnover
• Safety: No dose-limiting toxicity; no deaths; mild-moderate infusion-related reactions (20%); transient ALT ≤2.4×ULN (peak day 3–4, resolved by day 8); no thrombocytopenia (improvement over predecessor VERVE-101 formulation)
• Germline safety: No transmission of Pcsk9 edit in offspring of treated mice — consistent with absence of germline editing
• Regulatory requirement: All participants entering 15-year long-term follow-up for off-target editing surveillance (sources/verve102-pcsk9-nejm-2026 — high)

Projected clinical impact: A sustained LDL-C reduction of 78 mg/dL over 20 years is predicted to reduce ASCVD risk by >50% in most patients with hypercholesterolaemia. VERVE-201 (same GalNAc-LNP platform; targets ANGPTL3; NCT06451770) is a parallel programme for HoFH patients where LDLR-dependent strategies fail.

Status: Investigational only; Phase 1; no guideline recommendation; not approved; Heart-2 study ongoing (up to 85 participants). See concepts/Lipid-Gene-Therapy for the full class context including ANGPTL3 and LPA base editing programmes.

Obicetrapib (CETP Inhibitor)

• Obicetrapib 10 mg OD added to maximum tolerated lipid-lowering therapy in patients with established ASCVD or HeFH reduced LDL-C by 29.9% vs a placebo-group increase of 2.7%; between-group difference −32.6 pp (P<0.001) at Day 84 sources/obicetrapib-broadway-nejm-2025 (high)
• Simultaneously lowers Lp(a) by 33.5%, ApoB by 18.9%, non-HDL-C by 29.4%, and triglycerides by 7.8% — while raising HDL-C by 136.3% (CETP class effect)
• Safety comparable to placebo; no adverse metabolic, hepatic, renal, or aldosterone signals; new-onset diabetes/worsening glycaemia numerically lower than placebo (35.1% vs 40.0%)
• Not yet guideline-recommended; not yet approved — awaiting BROOKLYN cardiovascular outcomes trial (NCT05202509)
• Fills a niche between ezetimibe (~18% reduction) and injectable PCSK9 inhibitors (~45–64%) as an oral option; distinguished from both by simultaneous Lp(a) lowering
• See concepts/CETP-Inhibitors for full class history and mechanism

Contradictions / Open Questions

• Ez-PAVE: benefit driven by revascularisation (open-label bias risk) and target achievement gap: The primary composite benefit in Ez-PAVE (HR 0.67; P=0.002) was driven predominantly by revascularisation (HR 0.63) and nonfatal MI (HR 0.46), with no significant reduction in CV death, stroke, or UA hospitalisation individually. In an open-label trial, knowledge of the assigned LDL-C target could influence the threshold at which physicians refer patients for revascularisation — a particular concern when revascularisation is the dominant endpoint driver. Additionally, only 60.8% of the intensive group reached the <55 mg/dL target at 3 years (vs 68.1% reaching <70 mg/dL in the conventional group), diluting the true between-target comparison. The benefit represents the best achievable with limited PCSK9i access; broader PCSK9i/inclisiran/bempedoic acid use could widen both target attainment and clinical benefit. (sources/intensive-ldl-ezpave-nejm-2026, rating: high)
• Ez-PAVE generalisability: East Asian-only population and 3-year follow-up: Ez-PAVE enrolled exclusively Korean patients, who may have different cardiovascular risk profiles, statin pharmacokinetics (East Asians typically achieve higher statin blood levels at equivalent doses, potentially reaching LDL-C goals more readily), and comorbidity burden. Prior East Asian statin trials have shown results generally consistent with Western populations, but direct extrapolation to European or North American ASCVD populations requires caution. The 3-year median follow-up may be insufficient to detect differences in mortality endpoints that typically separate over longer periods. (sources/intensive-ldl-ezpave-nejm-2026, rating: high)
• REDUCE-IT placebo controversy: Mineral oil placebo caused deleterious lipid/inflammatory changes in the control arm, possibly exaggerating IPE benefit; true benefit magnitude uncertain. No validation from STRENGTH trial (omega-3+DHA negative). ESC 2025 acknowledges discordance but still recommends ICE (2×2 g/day) COR IIa B; ACC/AHA 2026 gives only COR 2b. sources/lipid-aha-2026 sources/lipid-esc-2025 (both very high)
• Inclisiran CVOT weaker than mAbs (ORION-4, Lancet 2024): ORION-4 (n=15,000) HR 0.84 (P=0.01) — statistically neutral by pre-specified P<0.005 threshold, despite directionally favourable result. Inclisiran's CV outcomes evidence is weaker than evolocumab (FOURIER P<0.001) and alirocumab (ODYSSEY P=0.003). Whether the ~10 percentage-point lower LDL-C reduction (~50% vs ~60%), shorter effective biological duration, or different population explains the divergence from mAbs is unresolved. Current guideline positioning (COR 2b; lower than COR 2a PCSK9 mAbs) is consistent with this evidence hierarchy. (sources/inclisiran-orion-nejm-2020 — high)
• VERVE-102 PCSK9 base editing — no CV outcomes, no long-term safety data: Heart-2 Phase 1 (NEJM 2026) establishes dose-dependent, durable LDL-C lowering to 18 months from a single infusion, but is phase 1 with n=35, no placebo control, and no MACE endpoint. Off-target editing causing delayed malignancy is theoretically possible but has not been reported in humans; FDA mandates 15-year minimum follow-up. Phase 1-to-Phase 3 safety extrapolation may be unreliable (precedent: MAGNITUDE nex-z Phase 3 hepatotoxicity after clean Phase 1). The single-infusion convenience vs well-characterised long-term CVOT evidence of PCSK9 mAbs/inclisiran represents an unresolved risk-benefit trade-off. (sources/verve102-pcsk9-nejm-2026 — high)
• Lp(a)-specific therapy: No definitive CVOT evidence yet for Lp(a)-lowering RNA therapies; phase 3 outcomes trials ongoing
• Statin use in pregnancy: FDA removed pregnancy as contraindication in 2024 (ACC/AHA 2026); ESC 2025 does not address this; statins should be avoided while lactating
• Threshold for LLT at age <30: 30-year risk estimates available but clinical trial evidence for treatment at this age is sparse
• FCS treatment: volanesorsen (ESC/EMA) vs olezarsen (ACC/AHA/FDA): ESC 2025 recommends volanesorsen (anti-ApoC-III ASO, EMA-approved, COR IIa B) for FCS; ACC/AHA 2026 recommends olezarsen (anti-ApoC-III ASO, FDA-approved, COR 1) for FCS. Both target ApoC-III but are different molecules with different regulatory approvals — region-specific formulary access will determine clinical use sources/lipid-esc-2025 sources/lipid-aha-2026 (both very high)
• IPE recommendation strength discordance: ACC/AHA 2026 gives icosapent ethyl COR 2b (noting REDUCE-IT placebo controversy); ESC 2025 gives COR IIa B. Class difference reflects different weighting of the mineral oil placebo controversy
• Olezarsen in moderate HTG — efficacy without CV outcomes proof: ESSENCE-TIMI 73b (NEJM 2025) demonstrates compelling TG and remnant cholesterol reductions (~60 pp TG; ~70% remnant cholesterol) with no change in LDL-C — but the trial was not powered for MACE. Genetic APOC3 LOF data and TRL-remnant atherogenicity support CV benefit, but fibrates (which reduce TG by 20–50%) failed to reduce MACE on statin background — whether the far more potent APOC3 inhibition will succeed where fibrates failed requires a dedicated CVOT sources/olezarsen-essence-timi73b-nejm-2025 (high)

Connections

• Related to concepts/ASCVD-Risk-Assessment — PREVENT equations and CPR framework form the basis of treatment decisions
• Related to concepts/Lipoprotein-a — measurement recommendation, risk quantification, and management
• Related to concepts/Familial-Hypercholesterolemia — special management track with distinct treatment targets
• Related to concepts/Heart-Healthy-Dietary-Patterns — the 9-feature AHA dietary framework for CVD risk reduction; dietary fat quality and LDL-C evidence
• Related to entities/Heart-Failure — statins considered in HFrEF; HF is a high-risk feature in secondary prevention
• Related to entities/Atrial-Fibrillation — IPE and fish oil supplements both associated with AF risk
• Related to concepts/CETP-Inhibitors — obicetrapib as emerging oral nonstatin; 30% add-on LDL-C reduction + Lp(a) lowering; BROADWAY 2025
• Related to concepts/PCSK9-Inhibitors — FOURIER/ODYSSEY outcome trial details; inclisiran ORION-10/11 Phase 3; genotype-specific HoFH dosing; safety profile; LDL-C target evidence down to <10 mg/dL
• Related to entities/Inclisiran — GalNAc-siRNA PCSK9 inhibitor; ORION-10/11 full Phase 3 data; ORION-4 CVOT; HCP-administered Q6-month schedule
• Related to concepts/Lipid-Gene-Therapy — PCSK9 base editing (VERVE-102); ANGPTL3 and LPA editing programmes; comparison of LNP/GalNAc platforms

Sources

• sources/intensive-ldl-ezpave-nejm-2026 — Ez-PAVE RCT; first direct <55 vs <70 mg/dL LDL-C target comparison; HR 0.67 (P=0.002); revascularisation-driven; East Asian
• sources/obicetrapib-broadway-nejm-2025 — BROADWAY RCT; obicetrapib −32.6 pp LDL-C; Lp(a) −33.5%; CV outcomes trial pending
• sources/olezarsen-essence-timi73b-nejm-2025 — ESSENCE-TIMI 73b Phase 3 RCT; olezarsen −58–61 pp TG; remnant cholesterol −70%; 85–89% TG normalization; no CV outcomes
• sources/ACS-AHA-2025
• sources/CCS-AHA-2023
• sources/diet-aha-2026
• sources/lipid-aha-2026
• sources/lipid-esc-2025
• sources/pcsk9-inhibitors-nrc-2018 — FOURIER and ODYSSEY Outcomes CVOT data; PCSK9 mechanism; very-low LDL-C target evidence; inclisiran Phase II
• sources/inclisiran-orion-nejm-2020 — ORION-10 and ORION-11 Phase 3 RCTs; inclisiran efficacy (−52.3%/−49.9% LDL-C), safety, mechanism, ORION-4 CVOT result (high)
• sources/verve102-pcsk9-nejm-2026 — Heart-2 Phase 1; VERVE-102 PCSK9 base editing; dose-response (−88% PCSK9/−62% LDL-C/−78 mg/dL at 1.0 mg/kg), safety, 18-month durability (high)